Gain Therapeutics, Inc. (GANX): Price and Financial Metrics
GANX Price/Volume Stats
| Current price | $1.77 | 52-week high | $3.19 |
| Prev. close | $1.79 | 52-week low | $0.89 |
| Day low | $1.62 | Volume | 784,200 |
| Day high | $1.83 | Avg. volume | 259,830 |
| 50-day MA | $1.86 | Dividend yield | N/A |
| 200-day MA | $1.97 | Market Cap | 53.00M |
GANX Stock Price Chart Interactive Chart >
Gain Therapeutics, Inc. (GANX) Company Bio
Gain Therapeutics, Inc., a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding. It has a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
GANX Price Returns
| 1-mo | -1.67% |
| 3-mo | -23.71% |
| 6-mo | 11.32% |
| 1-year | 37.21% |
| 3-year | -54.38% |
| 5-year | N/A |
| YTD | -18.06% |
| 2024 | -33.84% |
| 2023 | 4.31% |
| 2022 | -42.36% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...